Brokerages Set Boston Scientific Corporation (NYSE:BSX) Price Target at $92.29

Shares of Boston Scientific Corporation (NYSE:BSX) have been assigned an average rating of “Moderate Buy” from the twenty-eight analysts that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation, twenty-two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $87.4583.

Several equities research analysts have recently commented on the company. UBS Group decreased their price target on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. National Bank Financial set a $115.00 target price on Boston Scientific in a research note on Monday, February 2nd. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Evercore reduced their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Finally, Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight/hold and lowered its outlook on the stock, citing rising uncertainty around the company’s electrophysiology business and WATCHMAN growth. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Reuters reported Boston Scientific hit a two-year low after flagging weaker demand for its WATCHMAN heart device, adding to investor concern that a core growth driver is slowing. Boston Scientific hits two-year low after flagging weaker demand for heart device
• Negative Sentiment: The company’s 2026 guidance was reiterated, but investors viewed it as underwhelming given the slowdown in WATCHMAN and softer urology demand, which hurt sentiment further. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
• Negative Sentiment: Analyst commentary from Zacks said Boston Scientific and Abbott both posted solid growth, but Boston Scientific is facing mounting operational pressures, which may be limiting upside near term. BSX vs. ABT: Which Medical Stock Has More Upside Potential?
• Positive Sentiment: Despite the selloff, Boston Scientific’s clinical pipeline remains active, with updates on the FARAPULSE PFA atrial fibrillation study and a painful diabetic neuropathy trial milestone that could support future growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation Boston Scientific Nears Key Data Milestone in Painful Diabetic Neuropathy Trial
• Positive Sentiment: Unusually large call-option buying suggests some traders are positioning for a rebound in BSX after the recent weakness. Investors Buy Large Volume of Call Options on Boston Scientific (NYSE:BSX)

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $48.32 on Thursday. The business’s 50 day simple moving average is $60.23 and its 200-day simple moving average is $78.62. The firm has a market capitalization of $71.82 billion, a price-to-earnings ratio of 20.22, a price-to-earnings-growth ratio of 0.89 and a beta of 0.62. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific has a 12 month low of $48.13 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts forecast that Boston Scientific will post 3.37 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In other news, Director David C. Habiger acquired 2,250 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the acquisition, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Cheryl Pegus acquired 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 9,800 shares of company stock worth $554,012. Insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Institutional investors and hedge funds have recently made changes to their positions in the company. Claret Asset Management Corp increased its holdings in Boston Scientific by 4.4% in the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after purchasing an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC grew its stake in shares of Boston Scientific by 5.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after acquiring an additional 103 shares in the last quarter. Outfitters Financial LLC grew its stake in shares of Boston Scientific by 0.5% during the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock valued at $2,291,000 after acquiring an additional 110 shares in the last quarter. Fayez Sarofim & Co grew its stake in shares of Boston Scientific by 2.1% during the third quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock valued at $520,000 after acquiring an additional 111 shares in the last quarter. Finally, Natural Investments LLC grew its stake in shares of Boston Scientific by 2.9% during the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after acquiring an additional 112 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.